Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Multidisciplinary Approaches to Translational Research In Conduct Syndromes (MATRICS)

Date du début: 1 mars 2014, Date de fin: 28 févr. 2019,

Conduct Disorder (CD) is the key paediatric disorder characterized by severe aggression. It is heterogeneous, and our understanding of the neurobiology to subtype aggression is limited. MATRICS is a multidisciplinary consortium of academic partners and SMEs that focuses on the subtyping of aggression both within CD and of the broader cross-disorder trait of aggression. MATRICS will test the hypoth ...
Voir le projet

 21

 TERMINÉ 

THE MILESTONE PROJECT: Managing the Link and Strengthening Transition from Child to Adult Mental Health Care (MILESTONE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

Transition to adulthood is the period of onset of most of the serious mental disorders that disable or kill in adult life. Current service configuration of distinct Child and Adolescent Mental Health (CAMHS) and Adult Mental Health (AMHS) Services is considered the weakest link where the care pathway should be most robust. Transition-related discontinuity of care is a major socioeconomic and socie ...
Voir le projet

 14

 TERMINÉ 

DIabetes REsearCh on patient sTratification (DIRECT)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2019,

The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Voir le projet

 27

 TERMINÉ 

Aggression subtyping for improved insight and treatment innovation in psychiatric disorders (AGGRESSOTYPE)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Aggression is a basic physiological trait with important roles throughout evolution, both in defence and predation. When expressed in humans in the wrong context, aggression leads to maladjustment, social impairment and crime. Despite this, knowledge about aggression aetiology is limited and current treatment strategies are insufficient. Contingent to a subdivision into impulsive and instrumental ...
Voir le projet

 27

 TERMINÉ 

RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research (RD-CONNECT)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2018,

Despite examples of excellent practice, rare disease (RD) research is still mainly fragmented by data and disease types. Individual efforts have little interoperability and almost no systematic connection between detailed clinical and genetic information, biomaterial availability or research/trial datasets. By developing robust mechanisms and standards for linking and exploiting these data, RD-Con ...
Voir le projet

 30

 TERMINÉ 

A combined evolutionary and proteomics approach to the discovery, induction and application of antiviral immunity factors (Anti-Virome)

Date du début: 1 avr. 2013, Date de fin: 31 mars 2018,

"Humans are equipped with a variety of intrinsic immunity or host restriction factors. These evolved under positive selection pressure for diversification and represent a first line of defence against invading viruses. Unfortunately, however, many pathogens have evolved effective antagonists against our defences. For example, the capability of HIV-1 to counteract human restriction factors that int ...
Voir le projet

 1

 TERMINÉ 

A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF A MULTI-MODAL INTERVENTION IN OLDER PEOPLE WITH TYPE 2 DIABETES ON FRAILTY AND QUALITY OF LIFE: THE MID-FRAIL STUDY (MID-FRAIL-STUDY)

Date du début: 1 mars 2012, Date de fin: 30 avr. 2017,

The prevalence of diabetes in people ≥ 65 years approaches 25% (40% of all patients with diabetes are > 65 years). This number will increase 4-fold in people > 70 years in 2050. Diabetes results in a high personal and social health burden, and a significant public health burden in terms of rising healthcare costs. Diabetes is associated with increased functional decline in older people and may exp ...
Voir le projet

 17

 TERMINÉ 

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,

Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Voir le projet

 29

 TERMINÉ 

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease (NILVAD)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even modest therapeutic advances that delay disease onse ...
Voir le projet

 17

 TERMINÉ 

Orphans Unite: chILD better together – European Management Platform for Childhood Interstitial Lung Diseases (CHILD-EU)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2016,

Children with diffuse lung disease, also called childhood interstitial lung diseases (chILD), may have one of more than 200 entities, the biggest group of respiratory orphan lung diseases. Frequently undiagnosed because of lack of awareness or complex differential diagnosis, they lead to much morbidity, mortality (about 15%) and psychosocial stress for the families. Current lack of evidence based ...
Voir le projet

 10

 TERMINÉ 

Paving the way towards HIV eradication/control (HIT HIDDEN HIV)

Date du début: 1 déc. 2012, Date de fin: 31 oct. 2016,

Major advances in HIV/AIDS treatment regimens have fundamentally altered the natural history of the disease and sharply reduced HIV-related morbidity and mortality in countries where such treatments are accessible. The most notable advance is the use of combination antiretroviral therapy or ART. However, ART is unable to achieve virus eradication or “sterilizing cure”. Indeed, in most cases, viral ...
Voir le projet

 5

 TERMINÉ 

A BLUEPRINT of Haematopoietic Epigenomes (BLUEPRINT)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,

In response to the call for a high impact initiative on the human epigenome, the BLUEPRINT Consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and o ...
Voir le projet

 45

 TERMINÉ 

Interdisciplinary training network for Tourette Syndrome; structuring European Training capacities for neurodevelopmental disorders (TS-EUROTRAIN)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,

There is a striking lack in structured and standardized training infrastructure for neurodevelopmental disorders across Europe. Such training will be fundamental to promoting standards of care across Europe and will ultimately lead to strategies for the promotion of childhood mental health in Europe. The focus of this Initial Training Network (ITN) is Gilles de la Tourette Syndrome (TS), an inheri ...
Voir le projet

 12

 TERMINÉ 

MARie CuRIe AGEing Network (MARRIAGE)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,

"One of achievements of developed societies has been the remarkable extension of human lifespan. In the upcoming decades the number of Europeans with advanced age will increase dramatically. It is evident that age-associated diseases will become much more prevalent. This poses challenges for society but also opportunities for commercial enterprises that develop strategies to combat deleterious con ...
Voir le projet

 11

 TERMINÉ 

European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)

Date du début: 1 mars 2012, Date de fin: 30 juin 2016,

Diabetic retinopathy (DR), the leading cause of blindness among working-age individuals in developed countries has been classically considered to be a microcirculatory disease of the retina. However, there is growing evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR. For this reason, it is reasonable to hypothesize that therapeutic strategies based on n ...
Voir le projet

 18

 TERMINÉ 

Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2016,

Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain.Based on harmonised and standardised European population cohorts we have built significant research collabo ...
Voir le projet

 31

 TERMINÉ 

European multidisciplinary ALS network identification to cure motor neuron degeneration (Euro-MOTOR)

Date du début: 1 févr. 2011, Date de fin: 31 janv. 2016,

Amyotrophic Lateral Sclerosis is one of the most devastating diseases in neurology affecting in Europe 50,000 individuals at any time, and causing around 10,000 deaths each year. ALS is characterized by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS affects otherwise healthy people at any time in adulthood. The patient becomes paralyzed and dies ...
Voir le projet

 16

 TERMINÉ 

Realizing the European Network in Biodosimetry (RENEB)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

Creating a sustainable network in biological dosimetry that involves a large number of experienced laboratories throughout the EU will significantly improve the accident and emergency response capabilities in case of a large-scale radiological emergency. A well organised cooperated action involving EU laboratories will offer the only chance for a fast and trustworthy dose assessment urgently neede ...
Voir le projet

 28

 TERMINÉ 

Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates (TINN2)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

"The aim of TINN2 is to evaluate azithromycin, included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. Azithromycin is a macrolid antibiotic with anti-inflammatory properties active against Ureaplasma. It might be effective in reducing the severity of bronhopulmonary disease in which Ureaplasma infection and inflammation play a r ...
Voir le projet

 17

 TERMINÉ 

Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (NGS-PTL)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2015,

"Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and progression. A considerable heterogeneity can be further observed within the same hematological disease at the inter-individual level, being reflected by different clinical outcomes and responses to treatment in different patients. Nowadays, the advent of high-th ...
Voir le projet

 10

 TERMINÉ 

Evaluation of antibiotics (ciprofloxacin and fluconazole) for the treatment of infections in preterm and term neonates (TINN)

Date du début: 1 nov. 2008, Date de fin: 31 oct. 2015,

The aim of TINN is to evaluate ciprofloxacin, fluconazole and micafungin in neonates; two anti-infectious drugs included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. These drugs are prescribed off-label to treat neonatal infections that are life threatening situations and associated with long-term complications. In order to val ...
Voir le projet

 16

 TERMINÉ 

Nanosystems for the early Diagnosis of Neurodegenerative diseases (NADINE)

Date du début: 1 sept. 2010, Date de fin: 31 août 2015,

Medical diagnosis is currently undergoing a major revolution due to the fast discovery of molecular biomarkers, and the development of multimodal “metabiomarker” signatures. Progress, however, is hindered by low abundance of many biomarkers of interest in body fluids, in absolute concentration and with regard to other biomolecules. The aim of the present project is to apply these progresses in bio ...
Voir le projet

 19

 TERMINÉ 

Regenerating Bone defects using New biomedical Engineering approaches (REBORNE)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,

Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone replacement materials is currently estimated at 5 billion € with a 10% annual growth. Despite their considerable disadvantages, including the risk of disease transfer and immunologic rejection, limited supply of bone, costs and complications, allografts and autogra ...
Voir le projet

 24

 TERMINÉ 

New approaches for the targeted therapy of Non-Small Cell Lung Cancer (LUNGTARGET)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2015,

Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr). Non-small cell lung cancer (NSCLC) consists 85% of the cases, with 5 yr survival
Voir le projet

 10

 TERMINÉ 

Paediatric European Risperidone Studies (PERS)

Date du début: 1 mai 2010, Date de fin: 30 avr. 2015,

"Second-generation antipsychotics are increasingly being prescribed to children and adolescents. Their use, however, is mostly off-label, and adequate and sufficient data about efficacy and particular safety are lacking. This proposal focuses on two indications, the use of risperidone in children and adolescents with conduct disorder who are not mentally retarded, and the use of risperidone in ado ...
Voir le projet

 22

 TERMINÉ 

Suicidality: Treatment Occurring in Paediatrics (STOP)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,

The emergence of suicidality in patients receiving drug treatment is of concern because of the overall burden and the possible link with completed suicide. The lack of uniform requirements for defining, detecting and recording suicidality and the presence of disease related confounders create major problems. It is possible that Medication-Related Suicidality (MRS) differs from Psychopathology-Rela ...
Voir le projet

 19

 TERMINÉ 

Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,

"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet

 39

 TERMINÉ 

Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington’s Disease by SEN0014196 (PADDINGTON)

Date du début: 1 juil. 2010, Date de fin: 31 déc. 2013,

"The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington’s Disease. SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the ...
Voir le projet

 5

 TERMINÉ 

Constitutive receptor desensitization as molecular mechanism underlying cardia bifida (GPCR desensitization)

Date du début: 1 déc. 2010, Date de fin: 30 nov. 2013,

7TM receptors are called GPCRs because they require interaction with heterotrimeric G proteins to signal. In humans the family of GPCRs is comprised of more than 800 members. Despite their large number, GPCRs share high sequence homology and rely on an amazingly small assortment of accessory molecules to regulate their ability to signal. One such regulatory protein family is the family of G protei ...
Voir le projet

 1

 TERMINÉ 

European Collaborative Project on Inflamation and Vascular Wall Remodelling in Atherosclerosis (ATHEROREMO)

Date du début: 1 mai 2008, Date de fin: 31 oct. 2013,

"The health of the EC population has never been better. However, serious public health problems remain, which cannot be ignored including high levels of premature death due to cardiovascular diseases. Thus, new preventive, diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases are needed. The atherosclerotic changes of the vascular wall are central in the developmen ...
Voir le projet

 19

 TERMINÉ 

Multi-disciplinary biodosimetric tools to manage high scale radiological casualties (MULTIBIODOSE)

Date du début: 1 mai 2010, Date de fin: 30 avr. 2013,

"In the event of a large scale radiological emergency biological dosimetry is an essential tool that can provide timely assessment of radiation exposure to the general population and enable the identification of those exposed people, who should receive medical treatment. A number of biodosimetric tools are potentially available, but they must be adapted and tested for a large-scale emergency scena ...
Voir le projet

 17

 TERMINÉ 

A pharmacogenomic approach to coumarin anticoagulant therapy (EU-PACT)

Date du début: 1 oct. 2008, Date de fin: 31 mars 2013,

"The effectiveness of treatment with oral anticoagulants in the prevention of thrombotic disorders is well established, but these drugs are potentially dangerous because of their narrow therapeutic index. In Europe three coumarins are used: warfarin, acenocoumarol, and phenprocoumon. Genetic factors that have been recently demonstrated to change the pharmacokinetics and pharmacodynamics of coumari ...
Voir le projet

 12

 TERMINÉ 

Disc-degeneration linked pathologies: novel biomarkers and diagnostics for targeting treatment and repair (Genodisc)

Date du début: 1 mars 2008, Date de fin: 28 févr. 2013,

Disorders arising from degeneration of the intervertebral disc are an enormous clinical and financial burden on European societies. Most of the burden arises from 10% of patients who become chronically disabled. Any factor which will improve treatment of back pain sufferers or prevent development of chronic disability would have an important impact both on society and in improving quality of life ...
Voir le projet

 10

 TERMINÉ 

European Study of Cohorts for Air Pollution Effects (ESCAPE)

Date du début: 1 juin 2008, Date de fin: 30 nov. 2012,

"European policy making is hampered by considerable uncertainty about the magnitude and nature of the impacts of long term exposure to air pollution on human health. ESCAPE is a collaboration of more than 30 European cohort studies including some 900,000 subjects. It is aimed at quantifying health impacts of air pollution and at reducing uncertainty. ESCAPE will also test new hypotheses on specifi ...
Voir le projet

 26

 TERMINÉ 

Novel biofunctional high porous polymer scaffolds and techniques controlling angiogenesis for the regeneration and repair of the degenerated intervertebral disc (Disc Regeneration)

Date du début: 1 nov. 2008, Date de fin: 31 oct. 2012,

30% of European workers experience back pain, and it is the most frequently reported work-related disorder. The proposed work seeks to provide a cure for lower back pain by developing porous scaffolds and technology which will repair a damaged intervertebral disc (IVD) by enabling its regeneration to a natural healthy state or better. Injectable acellular and cell-loaded bioactive polymer-based sc ...
Voir le projet

 17

 TERMINÉ 

Clinical decision making and outcome in routine care for people with severe mental illness (CEDAR)

Date du début: 1 avr. 2009, Date de fin: 30 sept. 2012,

"Background: A considerable amount of research has been conducted on clinical decision making (CDM) in short-term physical conditions. However, there is a lack of knowledge on CDM and its outcome in long-term illnesses, especially in care for people with severe mental illness. Thus, this project entitled ""Clinical decision making and outcome in routine care for people with severe mental illness"" ...
Voir le projet

 6

 TERMINÉ 

Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)

Date du début: 1 févr. 2009, Date de fin: 31 mars 2012,

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Voir le projet

 19

 TERMINÉ 

Mechanisms of early protective exposures on allergy development (EFRAIM)

Date du début: 1 févr. 2008, Date de fin: 31 janv. 2012,

Allergy has developed into a major health concern in Europe. Allergic diseases can currently be managed effectively but not cured. The onset of allergies stars early in life and there is increasing evidence that exogenous factors affecting the incidence of these illnesses exert their effect early in life, in part even prenatally. The highly interdisciplinary EFRAIM project will prospectively inves ...
Voir le projet

 15

 TERMINÉ 

"Apoptosis systems biology applied to cancer and AIDS. An integrated approach of experimental biology, data mining, mathematical modelling, biostatistics, systems engineering and molecular medicine" (APO-SYS)

Date du début: 1 févr. 2008, Date de fin: 31 janv. 2012,

"A Europe-wide consortium of experimental biologists, biomathematicians, biostatisticians, computer scientists and clinical scientists will team up to approach cell death pathways in health and disease, placing particular emphasis on cancer and AIDS. The consortium will create a unique database integrating existing and accumulating knowledge on lethal signal transduction pathways leading to apopto ...
Voir le projet

 24

 TERMINÉ 

Services and Health for Elderly in Long TERm care (SHELTER)

Date du début: 1 janv. 2009, Date de fin: 31 déc. 2011,

"One of the most relevant obstacle to assess and compare nursing home (NH) services and patients across countries relates to the fact that standardized and validated methodologies are not routinely in use in daily practice in Europe. The Minimum Data Set (MDS) is a comprehensive assessment instrument which contains a standardized set of essential clinical and functional status measures and allows ...
Voir le projet

 8